Last reviewed · How we verify
NCT04634630
The Influence of Cancer Stem-cells on Risk of Relapse in Patients Harboring Adenocarcinoma and Squamous Cell Carcinoma of the Lung
trial testing Exposure to lung cancer stem cells in Lung Cancer, Nonsmall Cell in 35 participants. Completed in 17 October 2020.
17 October 2020
Quick facts
| Lead sponsor | Beatrice Aramini |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 35 |
| Start date | 17 October 2017 |
| Primary completion | 17 October 2020 |
| Estimated completion | 17 October 2020 |
| Sites | 1 location across Italy |
Drugs / interventions tested
- Exposure to lung cancer stem cells
Conditions studied
- Lung Cancer, Nonsmall Cell — all drugs for Lung Cancer, Nonsmall Cell →
- Relapse/Recurrence — all drugs for Relapse/Recurrence →
- CSC — all drugs for CSC →
Sponsor
Beatrice Aramini
Who can join
Adults 18 to 85, any sex, with Lung Cancer, Nonsmall Cell or Relapse/Recurrence. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The present study is a prospective cohort study. The aim is to assess the relationship between the presence of cancer stem-cells (CSC) and the risk of relapse in patients with early and locally advanced adenocarcinoma and squamous cell carcinoma of the lung
Publications & conference data
3 peer-reviewed publications reference this trial (live from Europe PMC):
-
ALDEFLUOR activity, ALDH isoforms, and their clinical significance in cancers.
Duan JJ, Cai J, Gao L, Yu SC. · · 2023 · cited 21× · PMID 36651035 · DOI 10.1080/14756366.2023.2166035 -
The Influence of Cancer Stem Cells on the Risk of Relapse in Adenocarcinoma and Squamous Cell Carcinoma of the Lung: A Prospective Cohort Study.
Masciale V, Banchelli F, Grisendi G, D'Amico R, et al · · 2022 · cited 17× · PMID 35356974 · DOI 10.1093/stcltm/szab029 -
Cancer Stem Cells and Cell Cycle Genes as Independent Predictors of Relapse in Non-small Cell Lung Cancer: Secondary Analysis of a Prospective Study.
Masciale V, Banchelli F, Grisendi G, D'Amico R, et al · · 2022 · cited 3× · PMID 35674389 · DOI 10.1093/stcltm/szac040
Verify or expand the search:
- PubMed search for NCT04634630
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Lung Cancer, Nonsmall Cell
Currently open trials in the same condition.
- NCT06996249 — Prospective Data Collection Initiative on Thoracic Malignancies · recruiting
- NCT06426511 — ctDNA-MRD Guided Consolidation Toripalimab in Stage IB-IIIA NSCLC · Phase 2 · recruiting
- NCT06667154 — Efficacy Analysis of Neoadjuvant Treatment in Lung Cancer Using Low-dose Nivolumab Combined With Chemotherapy · Phase 2 · recruiting
- NCT05384873 — Immunonutrition for Improving the Efficacy of Immunotherapy in Patients With Metastatic Non-small Cell Lung Cancer · NA · recruiting
- NCT05537922 — I3LUNG: Integrative Science, Intelligent Data Platform for Individualized LUNG Cancer Care With Immunotherapy · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04634630 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Beatrice Aramini
- Last refreshed: 1 June 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04634630.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing